.Attributes Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of individuals with HER2+ sophisticated bosom cancer cells and active or stable mind metastases presented constant intracranial activity and wide spread effectiveness of T-DXd.